On August 12, 2021 INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, reported that Raymond J. Tesi, MD, President and CEO, will present at the Canaccord Genuity 41st Annual Growth Conference being held August 10 – 12 (Press release, INmune Bio, AUG 12, 2021, View Source [SID1234586511]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Canaccord Genuity 41st Annual Growth Conference

Presentation Date: Wednesday, August 11, 2021
Presentation Time: 9:00 AM Eastern Time
Webcast: View Source

Please contact your representative at Canaccord Genuity to schedule a virtual one-on-one meeting with INmune Bio during the respective conference.